Emergency Care Research studies
Vaccine Effectiveness of BNT162b2 COVID-19 Vaccine Formulations among Kaiser Permanente Southern California Members
This study will evaluate Comirnaty VE. The primary objective is to estimate the VE annual BNT162b2 against SARS-CoV-2 acute respiratory infection (ARI) hospitalization in adults age> 18 years. The secondary objective is to estimate the VE of annual BNT162b2 against SARS-CoV-2 ARI emergency department (ED)/urgent care (UC) visit (without subsequent hospitalization) in adults age> 18 years.
Principal Investigator:
Sara Yee Tartof, PhD, MPHFunding Source:
Pfizer, Inc.Funding Years:
2025 - 2027Research Categories:
Comparative Effectiveness, COVID-19, Emergency Care Research, Hospital Research, Infectious Disease, Vaccine Safety and EffectivenessVaccine Effectiveness of BNT162b2 COVID-19 Vaccine Formulations among Kaiser Permanente Southern California Members
This study will evaluate Comirnaty VE. The primary objective is to estimate the VE annual BNT162b2 against SARS-CoV-2 acute respiratory infection (ARI) hospitalization in adults age> 18 years. The secondary objective is to estimate the VE of annual BNT162b2 against SARS-CoV-2 ARI emergency department (ED)/urgent care (UC) visit (without subsequent hospitalization) in adults age> 18 years.





